Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APOP
Previous Symbol
CUSIPN/A
Phone972-9974-1444
Debt
Debt-to-Equity RatioN/A
Current Ratio7.11
Quick Ratio7.11
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.00 per share
Price / Book3.11
Profitability
EPS (Most Recent Fiscal Year)($1.46)
Net Income$-8,140,000.00
Net MarginsN/A
Return on Equity-93.10%
Return on Assets-62.09%
Miscellaneous
Employees24
Outstanding Shares5,440,000
Market Cap$17.08 million
OptionableNot Optionable
CELLECT BIOTECH/S (NASDAQ:APOP) Frequently Asked Questions
What is CELLECT BIOTECH/S's stock symbol?
CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP."
How were CELLECT BIOTECH/S's earnings last quarter?
CELLECT BIOTECH/S (NASDAQ:APOP) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.01. View CELLECT BIOTECH/S's Earnings History.
When is CELLECT BIOTECH/S's next earnings date?
What price target have analysts set for APOP?
1 brokers have issued 1 year price objectives for CELLECT BIOTECH/S's stock. Their forecasts range from $12.00 to $12.00. On average, they expect CELLECT BIOTECH/S's stock price to reach $12.00 in the next year. This suggests a possible upside of 285.9% from the stock's current price. View Analyst Price Targets for CELLECT BIOTECH/S.
What is the consensus analysts' recommendation for CELLECT BIOTECH/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELLECT BIOTECH/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELLECT BIOTECH/S.
What are Wall Street analysts saying about CELLECT BIOTECH/S stock?
Here are some recent quotes from research analysts about CELLECT BIOTECH/S stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We value Cellect based on a discounted cash flow (DCF) approach that assigns a total value of $120M to Cellect’s platform. Our valuation translates into a price per ADS of $14.00, taking into account roughly 8.8M fully-diluted ADSs outstanding as of mid-2019." (8/29/2018)
- 2. According to Zacks Investment Research, "Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. " (7/31/2018)
Has CELLECT BIOTECH/S been receiving favorable news coverage?
Media headlines about APOP stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CELLECT BIOTECH/S earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of CELLECT BIOTECH/S's key competitors?
Some companies that are related to CELLECT BIOTECH/S include iCAD (ICAD), Endologix (ELGX), Invo Bioscience (IVOB), Pro-Dex (PDEX), Repro-Med Systems (REPR), Motus GI (MOTS), CAS Medical Systems (CASM), Obalon Therapeutics (OBLN), Spectral Medical (EDTXF), Nephros (NEPH), SANUWAVE Health (SNWV), Restoration Robotics (HAIR), AIT Therapeutics (AITB), Lianluo Smart (LLIT) and Interpace Diagnostics Group (IDXG).
Who are CELLECT BIOTECH/S's key executives?
CELLECT BIOTECH/S's management team includes the folowing people:
- Mr. Kasbian Nuriel Chirich, Co-Founder & Exec. Chairman (Age 60)
- Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 60)
- Mr. Eyal Leibovitz, Chief Financial Officer (Age 57)
- Dr. Amotz Nechushtan, VP of R&D (Age 58)
- Dr. Tamara Byk-Tennenbaum, VP of Operations
How do I buy shares of CELLECT BIOTECH/S?
Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELLECT BIOTECH/S's stock price today?
One share of APOP stock can currently be purchased for approximately $3.11.
How big of a company is CELLECT BIOTECH/S?
CELLECT BIOTECH/S has a market capitalization of $17.08 million. The company earns $-8,140,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CELLECT BIOTECH/S employs 24 workers across the globe.
What is CELLECT BIOTECH/S's official website?
How can I contact CELLECT BIOTECH/S?
CELLECT BIOTECH/S's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]
MarketBeat Community Rating for CELLECT BIOTECH/S (NASDAQ APOP)
MarketBeat's community ratings are surveys of what our community members think about CELLECT BIOTECH/S and other stocks. Vote "Outperform" if you believe APOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
